Skin appendage disorder

This study tests an oral drug called VDPHL01 in 552 women aged 18–65 with mild to moderate hereditary hair loss. Participants take a pill once or twice daily for about 13 months. The goal is to see if it increases hair count and if women feel their hair looks better. It's a place…

This phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …

This pilot study tests whether injecting cyclosporine directly into the scalp can safely regrow hair in people with alopecia areata, an autoimmune disease causing patchy hair loss. Twelve adults with mild to moderate hair loss will receive either cyclosporine or saline injections…

This study tests a daily pill called upadacitinib for people with severe alopecia areata, an immune system attack on hair follicles causing at least 25% scalp hair loss. About 123 teens and adults in Japan will take either the drug or a placebo for up to 104 weeks to see if it sa…

This early-stage trial tests a new drug called VIS171 in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care,…

This study tests an experimental drug called rezpegaldesleukin in 94 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Participants receive either the drug or a placebo for 36 weeks, with an optional extension. The main goal is to measu…

This early-stage study tests a new medicine called DR-01 in 81 adults with alopecia areata (patchy hair loss) or vitiligo (white patches on skin). The main goals are to check safety and see if the drug can improve hair regrowth or skin color. Participants are randomly assigned to…

This pilot study tests the safety and effectiveness of baricitinib, a drug that targets inflammation, in 15 women with active frontal fibrosing alopecia (FFA). FFA is a condition that causes scarring and permanent hair loss, mainly at the front of the scalp and eyebrows. The stud…

This early-phase study tests whether azelaic acid gel, a topical medication already used for acne, can help women with central centrifugal cicatricial alopecia (CCCA) — a type of scarring hair loss that mainly affects Black women. Eighteen women will use the gel on their scalp on…

This study tests a daily oral medication called ritlecitinib in children aged 6 to 12 with severe alopecia areata, a condition causing significant hair loss. About 208 children will receive either a higher dose, lower dose, or placebo for 6 months. The goal is to see if the drug …

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This pilot study tests whether a daily plant-based serum can safely improve hair growth in 40 men and women with mild to moderate thinning hair. Participants apply the serum to their scalp for 9 months, and researchers measure changes in hair density and thickness using special c…

This pilot study tests whether a solution made from human amniotic fluid, called XVIE, can safely improve hair growth in women who feel their hair is thinning. Fifteen women will receive two treatments over four months, applied to the scalp via microneedling. Researchers will tra…

This study tests a drug called bempikibart (ADX-914) in 75 adults with severe alopecia areata, a condition causing significant scalp hair loss. In the first part, some participants received the drug and some a placebo to see if it helps hair regrow. The second part gives the drug…

This study monitors the long-term safety and effectiveness of the drug Litfulo (ritlecitinib) in 487 patients with alopecia areata, a condition causing patchy hair loss. Researchers will track side effects and measure hair regrowth using the SALT score, aiming for a score of 20 o…

This Phase 3 trial tests an oral drug called VDPHL01 in 480 men aged 18-65 with mild to moderate male pattern baldness. The study is double-blind and placebo-controlled, lasting about 13 months. Researchers will measure hair counts and patient satisfaction at 6 months to see if t…

This study compares two treatments for alopecia areata, a condition causing patchy hair loss. One group receives microneedling alone, while the other gets microneedling plus topical vitamin D3. The goal is to see if adding vitamin D3 leads to complete hair regrowth. Eighty adults…

This Phase 2 study tests an investigational oral drug called VDPHL01 in 70 adults with mild to moderate pattern baldness. Participants take a tablet once or twice daily for 12 months. Researchers will measure changes in hair count and ask participants about perceived benefit. The…

This study tests an experimental oral drug called VDPHL01 for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 6 months, then all will receive the active drug for another 6 months…

This study looks at the long-term safety and effectiveness of a drug called CTP-543 for adults with moderate to severe alopecia areata, a condition that causes patchy hair loss. About 1,000 people who already completed 24 weeks of treatment in a previous CTP-543 trial will contin…

This trial aimed to test a combination of platelet-rich plasma and stem cells from fat tissue for treating male and female pattern hair loss. It was designed to compare different mixtures injected into the scalp. However, the study was withdrawn before enrolling any participants,…

This study tests whether a daily supplement called Olistic Next Women can improve hair growth and reduce hair loss in women aged 50-65 who are starting to experience female pattern hair loss. Over 6 months, 100 women will take either the supplement or a placebo, and researchers w…

This study tests a daily supplement called Olistic Next Women in 60 women aged 45-65 who are starting to lose hair. For 6 months, some women get the supplement and others get a placebo. Researchers will measure hair density and shedding to see if the supplement helps without caus…

This study tests two ways to cool the scalp during chemotherapy to prevent hair loss in women with localized breast cancer. One uses a standard cold cap with a compression bandage, the other a cooling mask. Researchers will compare how well each prevents hair loss, and also look …

This pilot study tests whether Xtressé gummy supplements can safely improve hair growth in 60 women aged 18-65 who feel their hair is thinning. Participants take the gummies daily for 4 months, and researchers measure changes in hair density and thickness using special cameras. T…

This study tested if a scalp cooling cap set to a colder temperature than usual can safely prevent hair loss in breast cancer patients receiving chemotherapy. 34 adults with stage I-III breast cancer took part. The goal was to see if the lower temperature is safe and tolerable.

This early study tests whether a low-dose oral medication (minoxidil) can help regrow hair in people who have permanent hair loss after chemotherapy. Fourteen adults who finished chemo at least six months ago will take the pill and be checked every 12 weeks for hair regrowth and …

This study tests a dietary supplement containing taurine, L-cysteine, and grape seed extract to see if it improves hair health in people with hair loss. About 239 men and women will take either the active supplement or a placebo daily for 6 months. Researchers will measure hair d…

This study tests a portable scalp cooling system called Amma to see if it can prevent hair loss in women receiving chemotherapy for early-stage breast cancer. Forty women with stage I-III breast cancer will use the cooling cap during their chemo sessions. The goal is to see if mo…

This 3-month study tests two doses of a dietary supplement containing biotin, collagen, keratin, and hyaluronic acid in 40 adults aged 21-50 with self-perceived thinning hair. Participants take either a low or high dose daily, and researchers measure hair thickness and strength u…

This study tests whether applying exosomes (tiny particles from stem cells) to the scalp, along with microneedling and a cooling device, can improve hair density in adults with non-scarring hair thinning. About 15 healthy men and women will be randomly assigned to one of three tr…

This pilot study tests whether oral minoxidil can improve persistent hair loss in children and young adults who survived cancer. Ten participants aged 6-18 who completed cancer treatment at least a year ago will receive either minoxidil or a placebo for 4 months. Researchers will…

This study was designed to test whether a vibrating device called Buzzy can reduce pain during platelet-rich plasma (PRP) injections for hair loss. Researchers planned to treat half of each participant's scalp with the vibration and the other half without, then compare pain score…

This study tests whether a daily nutraceutical drink called Olistic Next Women can reduce hair loss and improve skin aging in women aged 50-65 with early female pattern hair loss. One hundred participants will take either the drink or a placebo for 6 months. Researchers will meas…

This study tests if the DigniCap scalp cooling system can prevent hair loss in Black women with early-stage breast cancer undergoing chemotherapy. About 30 participants will use the cooling cap during chemo sessions. The goal is to see if it helps keep hair, reducing the need for…

This study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …

This observational study examines whether certain blood markers (VEGF-A and VCAM-1) are linked to nailfold capillary changes in people with alopecia areata. Researchers will compare 90 participants (patients with acute or chronic alopecia areata and healthy volunteers) using bloo…

This study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …

This study follows 546 women with non-metastatic breast cancer to see how chemotherapy or endocrine therapy affects their hair, skin, and nails. Researchers will use clinical exams, photos, and questionnaires to track changes and identify who is most at risk. The goal is to bette…

This study is a long-term, online registry that collects information from 10,000 women in the U.S. to understand how lifestyle, environment, and age affect skin and hair health. Participants will use apps and web tools to share data. The goal is to build a knowledge base for rese…